The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Abstract
The regulatory approval of Onpattro, a lipid nanoparticle-based short interfering RNA drug for the treatment of polyneuropathies induced by hereditary transthyretin amyloidosis, paves the way for clinical development of many nucleic acid-based therapies enabled by nanoparticle...
Paper Details
Title
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Published Date
Dec 1, 2019
Journal
Volume
14
Issue
12
Pages
1084 - 1087
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History